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Abstract
Background: Individuals with coronary artery disease are at high risk for adverse health outcomes. This risk can be
diminished by aggressive lipid management, but adherence to lipid management guidelines is far from ideal and substantial
racial disparities in care have been reported. Lipid treatment and goal attainment information is not readily available for
large patient populations seen in the fee-for-service setting. As a result, national programs to improve lipid management
in this setting may focus on lipid testing as an indicator of lipid management. We describe the detection, treatment, and
control of dyslipdemia for African Americans and Caucasians with coronary artery disease to evaluate whether public
health programs focusing on lipid testing can eliminate racial disparities in lipid management.
Methods: Physicians and medical practices with high numbers of prescriptions for coronary artery disease medications
were invited to participate in the Quality Assurance Program. Medical records were reviewed from a random sample of
patients with coronary artery disease seen from 1995 through 1998. Data related to the detection, treatment, and
control of dyslipidemia were abstracted from the medical record and evaluated in cross-sectional stratified and logistic
regression analyses using generalized estimation equations.
Results: Data from the medical records of 1,046 African Americans and 22,077 Caucasians seen in outpatient medical
practices in 23 states were analyzed. African-American patients were younger, more likely to be women and to have
diabetes, heart failure, and hypertension. The low density lipoprotein cholesterol (LDL-C) testing rate for Caucasian men
was over 1.4 times higher than that for African-American women and about 1.3 times higher than that for African-
American men. Almost 60% of tested Caucasian men and less than half of tested African Americans were prescribed
lipid-lowering drugs. Tested and treated Caucasian men had the highest LDL-C goal attainment (35%) and African-
American men the lowest (21%).
Conclusions: Although increased lipid testing is clearly needed for African Americans, improvements in treatment and
control are also necessary to eliminate racial disparities in lipid management. Disparities in treatment and goal attainment
must be better understood and reflected in policy to improve the health of underserved populations.
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Individuals with coronary disease (CAD) are at high risk
for subsequent cardiovascular disease events and mortal-
ity[1]. Clinical trials have shown that this risk can be sub-
stantially reduced though the detection, treatment, and
control of dyslipidemia[2,3]. To that end, clinical guide-
lines have been established for the lipid management of
CAD patients[4,5]. Adherence to these guidelines is far
from ideal[6,7]. Substantial racial disparities in the diag-
nosis and management of dyslipidemia have been
reported in the general population and among CAD
patients [8-16].
Improved lipid management through the diagnosis of
dyslipidemia has been a focus of quality improvement
programs in the outpatient fee-for-service setting such as
Medicare's Health Care Quality Improvement Pro-
gram[17]. Lipid testing is used as an indicator of lipid
management in the fee-for-service setting because testing
is a service identifiable in insurance claims data. In con-
trast, assessment of treatment and goal attainment in the
fee-for-service setting requires resource-intensive medical
record review which is generally not performed for large
national patient populations.
This study describes outpatient lipid management for
African Americans and Caucasians with CAD seen in med-
ical practices throughout the United States. Data from
medical records were examined for indicators of lipid
management including lipid testing, lipid-lowering drug
prescription, and goal attainment. Our objectives were to
characterize lipid management across race-sex groups and
evaluate the extent of disparities for the three components
of lipid management: detection, treatment, and control.
We then discuss the implications of our findings with
respect to possible underlying causes and health policies
for closing the gap in race-sex lipid management
disparities.
Methods
The Quality Assurance Program
The Quality Assurance Program (QAP) is a national pro-
gram sponsored by Merck & Company conducted during
the late 1990's to identify physician practice patterns and
to promote evidence-based best practices for the medical
management of patients with cardiovascular disease seen
in the outpatient setting [18]. The QAP database provides
abstracted medical record data collected in two distinct
time periods and study populations nationwide. Our
analyses were limited to the study population identified
in the most recent period of data collection (QAP-II).
Patients from QAP-II included in these analyses were seen
at participating medical practices from January, 1995
through March, 1998.
Medical records were reviewed by Access Medical Ltd
(Arlington, VA) using a standardized electronic abstrac-
tion tool developed specifically for QAP-II. The QAP data-
base contains data obtained from the medical record
including race, sex, date of birth, medical history, and
medical procedures. The most recent serum lipid testing
results and the most recently recorded prescriptions for
lipid-lowering drugs were also determined from the med-
ical record. The medical record of each patient was
reviewed only once. Patients were not followed over time.
Patient and physician identifying information were not
included in the QAP-II database to ensure confidentiality.
QAP participant selection
Physicians and medical practices throughout the United
States with high numbers of prescriptions for medications
used in the treatment of cardiovascular disease were
invited to participate in the QAP. The specialties of partic-
ipating physicians included cardiology, internal medi-
cine, family medicine, and endocrinology. Patients with
cardiovascular disease were randomly selected within
each participating medical practice.
Inclusion and exclusion criteria
Patients included in the QAP study were at least 21 years
of age with CAD and/or heart failure and were seen at least
twice in two years by the participating physician. Patients
were excluded if the medical record indicated a terminal
illness, history of a transplant or awaiting transplant, or
deceased.
Patients without medical record documentation of CAD
were excluded from analysis. The presence of CAD was
ascertained during analysis from abstracted medical
record data based on medical history, International Classi-
fication of Diseases, Ninth Revision, Clinical Modification
diagnosis codes (410–414), and cardiac procedures con-
sistent with CAD (i.e., coronary artery bypass graft, angi-
oplasty, and stent).
Only patients with medical record documentation of Afri-
can-American or Caucasian race were included. To reduce
the influence of between-state variation in lipid manage-
ment from states that contribute little information about
African American populations, medical practices were
excluded if they were located in states with fewer than 10
African-American patients in QAP-II
Indicators of lipid management
Measures of detection (lipid testing), treatment (lipid-
lowering drug prescription), and control (goal attain-
ment) were the indicators of lipid management consid-
ered in this study. Low density lipoprotein cholesterol
(LDL-C) testing was measured as the percentage of
patients with at least one serum LDL-C value documentedPage 2 of 9
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(i.e., "treated" patients) was measured as the percentage of
patients with medical record documentation of at least
one prescription for a statin (3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor) or non-statin lipid drug
(e.g., gemfibrozil). Goal attainment among those with
documented LDL-C values was based on recommended
guidelines for patients with coronary artery disease (LDL-
C < 100 mg/dL)[5].
Analysis
We conducted a cross-sectional analysis of abstracted
medical record data obtained from QAP-II. Indicators of
lipid management (i.e., LDL-C testing, lipid-lowering
drug prescription, and LDL-C goal attainment rates) and
potential confounding or explanatory variables were
examined within strata of race and sex. Co-morbid condi-
tions including diabetes mellitus, myocardial infarction,
heart failure, and hypertension were identified from med-
ical history and diagnosis codes.
Logistic regression analyses were performed to evaluate
the associations of race and sex with each of three dichot-
omous lipid management indicators while controlling for
multiple confounding and explanatory variables. We
accounted for correlations within medical practices using
the generalized estimation equation (GEE) method[19].
This method was implemented in generalized linear mod-
els with PROC GENMOD of SAS Version 9 (SAS, Inc,
Cary, North Carolina) for logistic regression with corre-
lated data[20]. Separate models were run for each indica-
tor of lipid management as the dependent variable. The
entire study population was included for logistic regres-
sion analyses of LDL-C testing as the dependent variable.
Regression analyses with lipid-lowering drug prescription
as the dependent variable included only patients with
LDL-C tests. Regression analyses for LDL-C goal attain-
ment were limited to patients who received at least one
LDL-C test and had a documented prescription for a lipid-
lowering drug.
The independent variables included in the regression
models in addition to race and sex were age, medical his-
tory (diabetes mellitus, myocardial infarction, heart fail-
ure, hypertension), and geographic region of medical
practice. Logistic models predicting lipid-lowering drug
prescriptions included a term for serum LDL-C concentra-
tion in addition to the above variables. LDL-C concentra-
tion was included to control for the severity of
hyperlipidemia as a factor in the physician's decision to
treat with lipid-lowering drugs.
Results
Population characteristics
A total of 23,123 CAD patients with documented race and
sex seen by 1,171 physicians at 238 medical practices in
23 states were included in the study. Of these patients,
1,046 were African American and 22,077 were Caucasian.
African-American compared to Caucasian patients were
more likely to be women (53% versus 36%). The average
age for the study population was 69 years and ranged
from 22 to 97 years.
Within each race group, women were older than men on
average and within each sex group Caucasians were older
than African Americans (Table 1). The prevalence of co-
morbid conditions was high for all race-sex groups.
Despite their younger ages, African Americans were more
likely than Caucasians to have diabetes, heart failure, and
hypertension. Almost half of African-American women
and a third of African-American men had diabetes com-
pared to about a quarter of the Caucasian population.
About half of African-American men had heart failure and
over three quarters of African-American women had
hypertension. Consistent with the geographic distribution
of race-specific populations, African-American patients
were more likely seen in southern medical practices than
elsewhere.
Lipid testing
Within sex strata, the percent of patients with LDL-C tests
was lower for African-Americans compared to Caucasians
(Figure 1). Within race strata the percent of patients with
LDL-C tests was lower for women than for men. The LDL-
C testing rate for Caucasian men was over 1.4 times higher
than that for African-American women and about 1.3
times higher than that for African-American men.
Lipid treatment
Almost 60% of Caucasian men with LDL-C testing were
prescribed lipid-lowering drugs (Figure 1). The propor-
tion of tested Caucasian women receiving these drugs
(55%) was similar to, but slightly lower than that for Cau-
casian men. Less than half of tested African-American men
(47%) and women (46%) were prescribed lipid-lowering
drugs.
Goal attainment
Including those prescribed and not prescribed lipid-low-
ering drugs (Table 1), a quarter of Caucasian women and
less than 20% of African-American men and women
achieved the recommended LDL-C goal. But a higher pro-
portion (31%) of Caucasian men achieved goal. The
mean serum LDL-C concentration for Caucasian men
(117 mg/dL) was lower than that for Caucasian women
(125 mg/dL) and for African-Americans. Mean LDL-CPage 3 of 9
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Characteristic African Americans Caucasians
Women (n = 558) Men (n = 488) Women (n = 8,038) Men (n = 14,039)
Age (mean ± SEM) 66.8 ± 0.5 62.7 ± 0.6 72.1 ± 0.1 67.1 ± 0.1
Medical History
Diabetes Mellitus 43 33 25 21
Myocardial Infarction 38 47 40 48
Heart Failure 42 48 39 34
Hypertension 78 70 63 52
Region
Northeast 27 25 34 31
Midwest 24 30 31 33
South 42 36 22 23
West 8 8 13 13
Serum Lipid Levels
LDL-C (mean ± SEM mg/dl)† 131.3 ± 2.5 133.0 ± 2.5 124.8 ± 0.6 117.2 ± 0.3
LDL-C at goal (%)† 19 18 25 31
*Percent of race- and sex-specific total unless otherwise specified. †For patients with documented tests having valid values
Lipid Management among CAD patientsFigure 1
Lipid Management among CAD patients. Lipid testing, treatment, and goal attainment rates for African-American and 
Caucasian women (W) and men (M).
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(133 mg/dL) and women (131 mg/dL).
Among patients tested and treated with lipid-lowering
drugs about two-thirds or more failed to achieve goal (Fig-
ure 1). Tested and treated Caucasian men had the best
goal attainment rates (35%). Tested and treated Cauca-
sian women had lower levels of goal attainment than Cau-
casian men. Goal attainment for Caucasian men and for
women of either race exceeded that of African-American
men. Only about 1 of 5 African-American men prescribed
lipid-lowering drugs achieved LDL-C goal.
Logistic regression
Results from GEE logistic regression analyses controlling
for age, co-morbid conditions, and geographic region
(Table 2) were consistent with results from the stratified
analyses described above. Relative to Caucasians, African-
American men and women were under-tested, under-
treated, and less likely to be at goal. Relative to men,
regardless of race, women were less likely to be tested. But
if tested, women were as likely as men of the same race to
receive prescriptions for lipid-lowering drugs. African-
American women were the least likely to be tested (Odds
Ratio, OR = 0.49), and if tested, African-American men
were the least likely to be prescribed lipid drugs (OR =
0.59). Among those tested and treated, African-American
men were least likely to be at goal (OR = 0.47). That is,
among tested patients who were prescribed lipid-lowering
drugs, the odds for goal attainment for Caucasian men
were more than twice the odds for African-American men.
Discussion
Consistent with previous reports, our findings demon-
strate that outpatient lipid management for CAD patients
in the late 1990's had much room for improvement and
that substantial race-sex disparities existed[8,12,16,21-
26]. African Americans experienced markedly lower levels
of LDL-C testing than Caucasians and, as a result, they
may benefit more than Caucasians from interventions to
improve testing. Among those tested, African Americans
were less likely to be treated and, if treated, they were less
likely to be at goal compared to Caucasians. Marked lipid
testing disparities by sex suggest a need for more aggres-
sive testing in women.
Much of the information needed to assess lipid manage-
ment can be found only in the medical record. This infor-
mation is generally not available to national and local
public health programs attempting to implement policies
promoting quality improvement in the many and diverse
medical practices treating large patient populations. The
most readily available data for patients seen in the fee-for-
service setting is derived from administrative insurance
claims for the reimbursement of costs associated with
drugs and services. Insurance coverage for lipid-lowering
drugs varies across plans. In contrast, lipid testing for CAD
patients is a widely covered service that can be identified
using electronic billing data without the need to review
patient records in medical practices. For this reason, lipid
testing is a focus of national efforts in the Medicare popu-
lation to improve outpatient lipid management in the fee-
for-service setting[17]. Our findings demonstrate that
substantial disparities in treatment and goal attainment
exist among CAD patients with lipid tests. This implies
that current public health programs and policies designed
to increase lipid testing alone will have limited impact on
lipid management disparities. Substantial disparities in
lipid treatment and control will likely persist in the
absence of disparities in testing.
Underlying causes of inadequate lipid management
among CAD patients are multiple and likely vary by race
and process of care (i.e., detection, treatment, and con-
trol). Factors that limit patient-physician encounters and
continuity of care may partially account for racial
disparities in lipid management. For example, African-
American Medicare consumers with diabetes were more
Table 2: Lipid testing, pharmacologic treatment, and goal attainment among African-American men and women and Caucasian women 
relative to Caucasian men from logistic regression analyses.*
African American Caucasian
Women
Odds Ratio
(95% CI)*
Men
Odds Ratio
(95% CI)*
Women
Odds Ratio
(95% CI)*
Men
Reference Group
LDL-C tested (n = 23,104) 0.49 (0.37,0.64) 0.60 (0.47,0.77) 0.80 (0.74,0.86) 1.00
Lipid drug prescribed (n = 14,499)† 0.62 (0.46,0.83) 0.59 (0.45,0.78) 1.04 (0.95,1.13) 1.00
LDL-C goal attainment (n = 8,336) ‡ 0.55 (0.36,0.82) 0.47 (0.30,0.74) 0.76 (0.68,0.85) 1.00
*Odds ratio and 95% confidence intervals (95% CI) from logistic regression models accounting for within-practice correlations with GEE and 
controlling for race, sex, age, medical history (diabetes mellitus, myocardial infarction, heart failure, hypertension), and geographic region of medical 
practice. †Regression model includes serum LDL-C concentration. ‡LDL-C goal attainment (<100 mg/dL) among those with documented LDL-C 
values and treated with lipid-lowering drugs.Page 5 of 9
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ments and had fewer physician visits per year than their
Caucasian counterparts[12,27]. The QAP data provide
insufficient information to evaluate whether health care
access and continuity explain lipid management
disparities.
A report regarding racial disparities in the use of prescrip-
tion drugs from the Center for Studying Health System
Change provides evidence of other factors explaining
racial disparities in lipid management[11]. In this report,
Medicare consumers 65 years of age and older were sur-
veyed regarding their ability to obtain prescription drugs.
African Americans were more than twice as likely as Cau-
casians to have not filled a prescription because they
could not afford it. More than 16% of Medicare insured
African Americans reported that they could not afford to
fill at least one prescription in 2001. One-fifth of African
Americans and 13% of Caucasians with low income could
not afford to fill at least one prescription. During the time
period of QAP-II, Medicare did not cover the cost of lipid-
lowering drugs. Many Medicare consumers have supple-
mental insurance that assists with drug costs. In the Medi-
care population, African Americans were less likely than
Caucasians to have supplemental insurance and more
likely to be of low income[11].
Barriers to lipid management due to affordability may
result in racial disparities if affordability differs by race.
Patients who can not afford treatment may be less likely
to aggressively pursue it with their physicians and may be
less likely to comply with physician recommendations for
testing and treatment. Secondary prevention of cardiovas-
cular diseases among CAD patients with pharmacologic
agents such as statins has been shown to be cost effec-
tive[28]. But drug costs that may exceed $2,000 annually
can be beyond the reach of low income and underinsured
patients[29]. These costs are more likely a barrier for Afri-
can Americans than for Caucasians and may contribute to
lipid management disparities.
The fact that African Americans are more likely to be of
low income has greater implications than simply the ina-
bility to afford medications. Income is one of several indi-
cators of socioeconomic status correlated with factors
related to health including education[30]. Low education
has been identified as a factor limiting a patient's personal
involvement in lipid management[31]. There is evidence
that African Americans are less knowledgeable about cho-
lesterol compared to Caucasians[24]. African Americans
may be less aware of the need for lipid management and
less likely to pursue it with their physician.
Achieving LDL-C goal is challenging for all races, but Afri-
can Americans may require especially aggressive lipid
management accompanied by an enhanced
understanding of reasons for failure to achieve goal. A
recent report concerning patients with CAD and/or diabe-
tes seen at a Veterans Affairs Medical Center found that
African Americans were less likely to achieve lipid goal
than Caucasians when prescribed identical doses of the
same lipid-lowering drug even though African Americans
had more clinic visits and lipid tests[10]. The authors
speculate that racial disparities in goal attainment may
have occurred due to differences in compliance, lifestyle,
and baseline LDL-C (higher for African Americans). In a
study of LDL-C lowering with pravastatin in an African-
American population, only 13% of patients with a LDL-C
goal of 100 mg/dL actually achieved it. Incorrect drug reg-
imen, inadequate lipid monitoring, and compliance
problems were thought to have contributed to these goal
attainment failures[32]. Additional studies are needed to
investigate the underlying causes of lower goal attainment
for African Americans receiving treatment for
dyslipidemia.
Physicians have indicated that oversight is a common rea-
son for failure to adhere to lipid testing guidelines[33].
Whether oversight contributes to racial disparities in lipid
management is not known, but oversight can be alleviated
by system changes in the medical practice[34]. Awareness
is growing that implementation of electronic health
records is a necessary component of efforts to improve
healthcare quality and prevent medical errors[35,36]. The
impact of electronic systems on disparities is an interest-
ing area for future research. Lipid management is also
influenced by physician attitudes about guidelines and
drug effectiveness[37]. A better understanding is needed
of physician attitudes and their relations with healthcare
disparities.
Physician-patient interactions are influenced by race and
cultural factors related to race. African-American and Cau-
casian patients may differ with respect to cultural percep-
tions of health and disease and the ability of patients to
influence or control their health outcomes[38]. African
Americans may be less likely than Caucasians to trust their
physicians and racial groups may view their relationship
with physicians differently[39]. A survey of adults seen in
a managed care setting revealed that African Americans
viewed their visits with physicians as less participatory
than did Caucasians, but they felt more participatory
when seeing a physician of their own race[40].
The relatively poorer lipid management for African Amer-
icans compared to Caucasians may be partially explained
by racial differences in the prevalence of co-morbid con-
ditions. African Americans in the QAP were more likely
than Caucasians to suffer from multiple chronic condi-
tions including diabetes and heart failure. It has beenPage 6 of 9
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without diabetes receive poorer lipid management and
are less likely to be at goal[41]. An earlier report from the
QAP has shown that patients with CAD and heart failure
were less likely to receive lipid testing and cholesterol-
lowering drugs than those without heart failure[42]. Co-
morbid conditions may hinder lipid management in a
number ways. These patients may be more likely to have
contra-indications to lipid treatment and to present with
acute life-threatening conditions that divert attention
away from lipid management. In addition, it has been
reported that patients with multiple chronic conditions
are less likely to afford medications than those with one
or fewer chronic conditions[11]. But even after control-
ling for several highly prevalent co-morbid conditions in
logistic regression analyses, we find that significant lipid
management disparities persist.
There are a number of limitations in the QAP study design
and its population that potentially pose a threat to inter-
nal and external validity. These limitations suggest that
our findings may not reflect the experiences of the general
population. The medical practices included in the QAP
were restricted to those writing large numbers of prescrip-
tions for cardiovascular disease drugs. It is difficult to eval-
uate the impact of this selection bias, but we suspect that
medical practices included in the QAP represent the larger
and more sophisticated providers of care. Thus, lipid
management among QAP participants may be better than
that found in the general population. Another limitation
to our study is the lack of information characterizing med-
ical practices, physicians, and patients with respect to fac-
tors related to race, sex, and lipid management. Because of
the unavailability of this information, we could not iden-
tify underlying factors potentially explaining our findings.
Lipid management data for the QAP patients seeing
multiple physicians were unavailable from physicians not
participating in QAP and this may have influenced results
in an unpredictable manner.
Considering the relatively small proportion of the study
population identified as African American (<5%), it is
likely that African Americans in this study do not repre-
sent the national population. We have no specific infor-
mation about QAP medical practices or their patient
populations, but we speculate that African Americans in
the QAP were likely receiving better care on average than
their counterparts in the general population, especially
those with little or no access to outpatient care. If this is
true, then racial disparities in lipid management in the
general population may be even greater that those sug-
gested by our findings.
The time frame for this study includes years 1995 through
1998. Despite changes in guidelines and therapies since
that time, our findings remain relevant to current
practices. They provide historic context and baseline
measures of lipid management disparities necessary to
evaluate trends. In addition, they direct attention to the
persistent need to provide aggressive treatment to high
risk populations with CAD, especially African Americans
and women who continue to be underserved. Finally, they
highlight the growing view that public health strategies in
lipid management must shift focus from testing to treat-
ment and goal attainment[43].
Clearly, a multi-pronged approach including all three ele-
ments of the process of care (i.e., detection, treatment, and
control) is needed to improve lipid management for all
race-sex groups, and particularly for African Americans.
Although beyond the scope of this report, the application
of conceptual models to the process of care may be useful
in understanding how racial disparities arise at each step
of the process. Furthermore, policies addressing health
promotion and non-medical determinants of health such
as socioeconomic status, community environment, and
lifestyle choices need also be considered in confronting
these disparities[44,45].
Successful lipid management likely depends on a variety
of processes that determine the provision of medical serv-
ices including their availability, accessibility, and accepta-
bility. The substantial racial disparities in lipid
management among patients in contact with medical pro-
viders suggest that the effectiveness of medical services
and patient characteristics play a prominent role in lipid
management. Policies promoting appropriate delivery of
care through system change as well as those ensuring
equal access to care are required to eliminate lipid man-
agement disparities in the population of high-risk CAD
patients[34,46].
Conclusions
Our results suggest that policies and programs focusing
solely on the elimination of lipid testing disparities can
have only limited benefit in reducing the major disparity
in lipid management. The elimination of lipid manage-
ment disparities will require policies that view untested,
untreated, and under-treated individuals as separate pop-
ulations with unique challenges and solutions[43].
Disparities in testing are just one element in explaining
overall disparities in lipid management and ultimately, in
cardiovascular outcomes. Future research should address
patient, physician, and health system factors that lead to
lower rates of testing, treatment and goal attainment for
African Americans. Disparities in treatment and goal
attainment must be better understood and reflected in
policy in order to improve the health of underserved pop-
ulations through optimal lipid management.Page 7 of 9
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